Search

Your search keyword '"Yang, J.C."' showing total 1,101 results
Start Over Author "Yang, J.C."
1,101 results on '"Yang, J.C."'

251. Wavelet-based multiresolution algorithm for integral and boundary element equations in electric and magnetic field computations

Author

Shao, K.R., Yang, J.C., and Lavers, J.D.

Subjects
Business, Electronics, Electronics and electrical industries
Abstract

This paper presents the multiresolution algorithm for integral and boundary element formulations of electric and magnetic field problems. Incorporating the merits of entire domain and subsectional basis functions, a sparse matrix can be directly obtained. Thus, memory storage is reduced and, by using diagonal preconditioning, the solution of the equations can be accelerated. Index Terms--Electric and magnetic field computations, integral equation and boundary element methods, multiresolution, wavelet transforms.

Published
2002

255. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer

Author

Cole, D.J., Sanda, M.G., Yang, J.C., Schwartzentruber, D.J., Weber, Joseph, Ettinghausen, S.E., Pockaj, B.A., Kim, H.I., Levin, R.D., Pogrebniak, H.W., Balkissoon, J., Fenton, R.M., DeBarge, L.R., Kaye, J., Rosenberg, S.A., and Parkinson, D.R.

Subjects
Metastasis -- Care and treatment, Macrophage colony stimulating factor -- Dosage and administration, Health
Abstract

Background: Macrophage colony-stimulating factor is a bone marrow-derived glycoprotein that can stimulate monocytes and macrophages, resulting in production of factors involved in immune response. In vitro and in vivo preclinical studies in animals have demonstrated that recombinant human macrophage colony-stimulating factor (rHuM-CSF) can have antitumor activity. Purpose: A phase I clinical trial was undertaken to evaluate the toxicity, pharmacokinetics, and immunologic effects of rHuM-CSF given by continuous intravenous infusion in patients with cancer. Methods: Eighteen patients with metastatic solid tumors refractory to conventional therapy were treated with rHuM-CSF. Twelve patients received two 14-day cycles of rHuM-CSF by continuous infusion, with a 2-week interval. Dose escalation levels were 50, 100, and 150 [mu]g/kg over 24 hours. Consecutive cohorts of three to six patients were planned at each dose level. Six patients received a modified regimen of four 7-day periods of infusion at 100 [mu]g/kg over 24 hours, with 1-week intervals. Results: Dose-limiting toxicity was grade 4 thrombocytopenia at a dose of 150 [mu]g/kg over 24 hours in two patients receiving the 2-week regimen. Platelet count nadirs and concomitant monocytosis were seen on days 7-9, but recovery occurred during the treatment period. Macrophage colony-stimulating factor serum levels were maximal on day I and returned to near baseline on day 7 of infusion. Patients treated with four 7-day infusions had no treatment-limiting thrombocytopenia. There were no cumulative effects on platelet or monocyte counts or significant constitutional symptoms. Subclinical conjunctival injection was noted in rive of 10 patients receiving screening ophthalmologic evaluation. Grade 2 episcleritis was diagnosed in one patient, and asymptomatic perilimbal and retinal hemorrhages were seen in two. Two patients developed sepsis caused by the intravenous line, which required cessation of therapy. No objective responses were documented. Conclusion: The maximum tolerated dose of rHuM-CSF given by continuous intravenous infusion for 14 days was 100 [mu]g/kg over 24 hours, with rapidly reversible, dose-limiting thrombocytopenia at 150 [mu]g/kg over 24 hours. A regimen alternating weekly cycles of infusion avoids dose-limiting toxicity and allows long-term treatment. Implications: The regimen of repeated 7-day infusions may be useful for future studies evaluating rHuM-CSF-activated monocytes in therapy for long-term infectious diseases or in investigation of new modes of cancer therapy using rHuM-CSF in conjunction with a tumor-specific antibody. [J Natl Cancer Inst 86:39-45, 1994]

Published
1994

256. Relative stability of boiling on a flat plate: effects of heater orientation

Author

Lin, W.W., Yang, J.C., and Lee, D.J.

Subjects
Heating research -- Case studies, Thermal diffusivity -- Research, Engineering and manufacturing industries, Science and technology
Abstract

A study on the influence of heater orientation on boiling heat transfer efficiency was conducted to elucidate the relative stability between nucleate and film boiling on an inclined, conductively heated surface under a forced flow. Results indicated that coexisting heat fluxes were present at various configurations of the heater. The nucleate boiling mode exhibits the highest stability relative to its corresponding film boiling mode when the heater was placed horizontally with its surface turned vertically at its side.

Published
1999

257. Half-life measurement of short-lived $^{94m}_{44}Ru^{44+}$ using isochronous mass spectrometry

Author

Zeng, Q., Wang, M., Zhang, Y.H., Tu, X.L., Chen, X.C., Xu, X., Litvinov, Yu. A., Xu, H.S., Blaum, K., Chen, R.J., Fu, C.Y., Ge, Z., Huang, W.J., Li, H.F., Liu, J.H., Mei, B., Shuai, P., Si, M., Sun, B.H., Sun, M.Z., Wang, Q., Xiao, G.Q., Xing, Y.M., Yamaguchi, T., Yan, X.L., Yang, J.C., Yuan, Y.J., Zang, Y.D., Zhang, P., Zhang, W., Zhou, X.H., Centre de Sciences Nucléaires et de Sciences de la Matière (CSNSM), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), and Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11)

Subjects
[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]
Abstract

International audience; Decay of the 8+ isomer in fully stripped ions Ru44+94 is observed during its circulation in the experimental Cooler Storage Ring (CSRe) at the Heavy Ion Research Facility in Lanzhou (HIRFL). The Ru44+94 ions were produced via projectile fragmentation and stored in CSRe tuned into the isochronous ion-optical mode. The timing signals of the ions, passing through a time-of-flight detector, were consecutively registered and used to determine the variation of revolution time as a function of revolution number. A sudden change of the revolution time at a specific revolution was identified as a fingerprint of the Ru44+94 isomer decay. The isomeric half-life was deduced to be 102(17) μs, which agrees well with the theoretical expectation by blocking the internal conversion decay of the isomer. Our work proved the feasibility of studying decays of short-lived isomers in high atomic charge states using the isochronous mass spectrometry. In addition, Ru44+94m represents the shortest-lived nuclear state whose mass has ever been measured directly.

Published
2017

263. Dielectronic recombination at low energy range with Boron‐like Ar13+at the CSRm.

Author

Huang, Z.K., Wang, S.X., Wen, W.Q., Xu, X., Wang, H.B., Li, S., Dou, L.J., Khan, N., Mahmood, S., Zhu, X.L., Zhao, D.M., Mao, L.J., Ma, X.M., Li, J., Mao, R.S., Yang, J.C., Yin, D.Y., Yuan, Y.J., Chen, C.Y., and Zhu, L.F.

Subjects
STORAGE rings, ION recombination, ELECTRON beams, IONS spectra, RESONANCE, IONS
Abstract

In order to extend the dielectronic recombination (DR) experiments from the main cooler storage ring CSRm with intermediate charge state ions to the experimental cooler storage ring CSRe with highly charged ions and even radioactive ions, a test electron‐ion recombination experiment of B‐like Ar13+ ions was performed with a section of the new electron beam energy detuning system, which will be installed at the CSRe. We present the measured and also the calculated DR spectra for the ∆n = 0 resonances from 0 to 3 eV. The experimental results agree very well with the previous DR experimental data from CRYRING, and the energy resolution reached 30 meV full width at half maximum. This test experiment demonstrates that the reliability and stability of the newly developed electron beam energy detuning system are satisfactory for the upcoming DR experiments at the CSRe. However, we found large discrepancies between the experimental result and the calculation in both resonance positions and the intensities of the recombination spectrum below 0.7 eV, which indicate that precise calculation of the DR spectrum of multielectron ions is still a challenge. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

264. Wavelet-Galerkin method in solving dynamic electronmagnetic field problems

Author

Yang, J.C., Shao, K.R., and Lavers, J.D.

Subjects
Electromagnetic fields -- Analysis, Business, Electronics, Electronics and electrical industries
Abstract

This paper presents a wavelet-Galerkin method to solve dynamic electromagnetic field problems. It differs from some former methods which discretize the whole space domain using wavelet functions, however it discretizes the space domain with finite element, because of its flexibility to the boundary. At the same time, it introduces the scaling function as trial functions for time domain, which are space orthogonal along the real line but has poor ability to adapt complex boundaries. Thus, it corporates both's merits. The results are better without suffering too much calculation time.

Published
1997

266. A method to measure the transition energy γt of the isochronously tuned storage ring

Author

Chen, R.J., primary, Yan, X.L., additional, Ge, W.W., additional, Yuan, Y.J., additional, Wang, M., additional, Sun, M.Z., additional, Xing, Y.M., additional, Zhang, P., additional, Fu, C.Y., additional, Shuai, P., additional, Xu, X., additional, Zhang, Y.H., additional, Bao, T., additional, Chen, X.C., additional, Hu, X.J., additional, Huang, W.J., additional, Li, H.F., additional, Liu, J.H., additional, Livinov, Yu.A., additional, Livinov, S.A., additional, Mao, L.J., additional, Wu, B., additional, Xu, H.S., additional, Yang, J.C., additional, Yin, D.Y., additional, Zeng, Q., additional, Zhang, X.H., additional, Zheng, W.H., additional, Zhou, X.H., additional, and Zhou, X., additional

Published
2018
Full Text
View/download PDF

268. P2.07-027 Efficacy and Safety of Nivolumab Therapy for Advanced NSCLC in the Expanded Access Named Patient Program in Taiwan

Author

Liao, B., primary, Chiang, C., additional, Chen, P., additional, Shen, Y., additional, Chen, W., additional, Hung, J., additional, Rau, K., additional, Lai, C., additional, Chen, C., additional, Kuo, Y., additional, Tsai, Y., additional, Wu, S., additional, Lin, C., additional, Wei, Y., additional, Wu, M., additional, Tsao, S., additional, Tsao, T.C., additional, Ho, C., additional, Feng, Y., additional, Tsao, C., additional, Lin, M., additional, Chong, I., additional, Hsia, T., additional, Chu, N., additional, Chen, Y., additional, Yu, C., additional, and Yang, J.C., additional

Published
2017
Full Text
View/download PDF

269. PS02.20 Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm+) NSCLC in LUX-Lung 3, 6 and 7

Author

Sequist, L.V., primary, Wu, Y., additional, Schuler, M., additional, Kato, T., additional, Yang, J.C., additional, Tanaka, H., additional, Hida, T., additional, Lu, S., additional, Park, K., additional, Paz-Ares, L., additional, Laurie, S., additional, Bennouna, J., additional, Moro Sibilot, D., additional, Märten, A., additional, Tang, W., additional, Ehrnrooth, E., additional, Yamamoto, N., additional, and Nakagawa, K., additional

Published
2017
Full Text
View/download PDF

271. P3.01-039 Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm+) NSCLC: Analysis of Time on Treatment and OS

Author

Park, K., primary, Tan, E., additional, O’Byrne, K., additional, Zhang, L., additional, Boyer, M., additional, Mok, T., additional, Hirsh, V., additional, Yang, J.C., additional, Schuler, M., additional, Yamamoto, N., additional, Sequist, L., additional, Wu, Y., additional, Zhou, C., additional, Ehrnrooth, E., additional, Märten, A., additional, Tang, W., additional, and Paz-Ares, L., additional

Published
2017
Full Text
View/download PDF

272. OA 17.01 Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update

Author

Borghaei, H., primary, Langer, C., additional, Gadgeel, S., additional, Papadimitrakopoulou, V., additional, Patnaik, A., additional, Powell, S., additional, Gentzler, R., additional, Martins, R., additional, Stevenson, J., additional, Jalal, S., additional, Panwalkar, A., additional, Yang, J.C., additional, Gubens, M., additional, Sequist, L., additional, Awad, M., additional, Fiore, J., additional, Saraf, S., additional, Raftopoulos, H., additional, and Gandhi, L., additional

Published
2017
Full Text
View/download PDF

275. OA 05.03 Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients with EGFR Activating and T790M Mutations

Author

Park, K., primary, Azuma, K., additional, Tsai, C., additional, Seto, T., additional, Nokihara, H., additional, Yang, J.C., additional, Kim, S., additional, Murakami, H., additional, Nishio, M., additional, Kiura, K., additional, Inoue, A., additional, Takeda, K., additional, Kang, J., additional, Hayashi, H., additional, Nakagawa, T., additional, Kaneko, Y., additional, Akazawa, R., additional, Shimazaki, M., additional, Morita, S., additional, Fukuoka, M., additional, and Nakagawa, K., additional

Published
2017
Full Text
View/download PDF

277. P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC)

Author

Yang, J.C., primary, Reckamp, K., additional, Kim, Y., additional, Novello, S., additional, Smit, E., additional, Lee, J., additional, Su, W., additional, Akerley, W., additional, Blakely, C., additional, Bazhenova, L., additional, Chiari, R., additional, Hsia, T., additional, Golsorkhi, T., additional, Despain, D., additional, Shih, D., additional, Rolfe, L., additional, Popat, S., additional, and Wakelee, H., additional

Published
2017
Full Text
View/download PDF

278. P3.01-026 Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC

Author

Schuler, M., primary, Yang, J.C., additional, Sequist, L., additional, Wu, Y., additional, Zhou, C., additional, Geater, S., additional, Mok, T., additional, Tan, E., additional, Hu, C., additional, Yamamoto, N., additional, Feng, J., additional, O’Byrne, K., additional, Lu, S., additional, Hirsh, V., additional, Huang, Y., additional, Ellis, S., additional, Samuelsen, C., additional, Märten, A., additional, Fan, J., additional, Park, K., additional, and Paz-Ares, L., additional

Published
2017
Full Text
View/download PDF

279. OA 09.03 TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI

Author

Ahn, M., primary, Han, J., additional, Sequist, L., additional, Cho, B.C., additional, Lee, J.S., additional, Kim, S., additional, Su, W., additional, Tsai, C., additional, Yang, J.C., additional, Yu, H., additional, Horn, L., additional, Lee, K., additional, Haddad, V., additional, Frigault, M., additional, Ahmed, G., additional, Yang, L., additional, Ghiorghiu, D., additional, and Oxnard, G., additional

Published
2017
Full Text
View/download PDF

281. P3.01-075 Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm+ NSCLC

Author

Hirsh, V., primary, Tan, E., additional, Wu, Y., additional, Sequist, L., additional, Zhou, C., additional, Schuler, M., additional, Geater, S., additional, Mok, T., additional, Hu, C., additional, Yamamoto, N., additional, Feng, J., additional, O’Byrne, K., additional, Lu, S., additional, Huang, Y., additional, Sebastian, M., additional, Okamoto, I., additional, Dickgreber, N., additional, Shah, R., additional, Palmer, M., additional, Märten, A., additional, Massey, D., additional, Samuelsen, C., additional, and Yang, J.C., additional

Published
2017
Full Text
View/download PDF

285. Measurement of the lifetime and the proportion of 12 C 3+ ions in stored relativistic ion beams as a preparation for laser cooling experiments at the CSRe

Author

Wang, H.B., primary, Wen, W.Q., additional, Huang, Z.K., additional, Zhang, D.C., additional, Hai, B., additional, Zhu, X.L., additional, Zhao, D.M., additional, Yang, J., additional, Li, J., additional, Li, X.N., additional, Mao, L.J., additional, Mao, R.S., additional, Wu, J.X., additional, Yang, J.C., additional, Yuan, Y.J., additional, Eidam, L., additional, Winters, D., additional, Beck, T., additional, Kiefer, D., additional, Rein, B., additional, Walther, Th., additional, Loeser, M., additional, Schramm, U., additional, Siebold, M., additional, Bussmann, M., additional, and Ma, X., additional

Published
2017
Full Text
View/download PDF

294. 1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC

Author

Kim, H.R., Awad, M.M., Navarro, A., Gottfried, M., Peters, S., Csőszi, T., Cheema, P.K., Rodriguez-Abreu, D., Wollner, M., Yang, J.C-H., Mazieres, J., Orlandi, F.J., Luft, A., Gümüş, M., Kato, T., Kalemkerian, G.P., Luo, Y., Santorelli, M.L., Pietanza, M.C., and Rudin, C.M.

Published
2020
Full Text
View/download PDF

299. Étude de phase II « basket » évaluant l’efficacité de l’anticorps monoclonal bispécifique anti-HER2/HER3 MCLA-128 chez les patients atteints de tumeurs solides avancées présentant un réarrangement NRG1

Author

Schram, A.M., Drilon, A., Macarulla, T., O’ Reilly, E.M., Rodon, J., Wolpin, B., Ou, S.H., Kim, D.W., Yang, J.C., Lam Yick Ching, J., Varga, A., De Langen, A.J., Witteveen, P., Boni, V., Cerea, G., Duruisseaux, M., Liu, S., Wasserman, E., Hyman, D.M., and Tabernero, J.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results